Contact Us

Menactra
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

Cell Phone 

Street Address 

Zip Code 

City 

State 

Date(s) vaccine(s) administered:

Please further describe side effects:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Menactra

Menactra Side Effects Lawsuits | Side Effects: Guillain Barre Syndrome, GBS, Weakness, Abnormal Sensations, Sensations In Arms, Sensations In Legs

Facebook Twitter Stumble AddThis Social Bookmark Button Pin It Email to Friend Print Page
CLICK HERE TO DOWNLOAD OUR Menactra INFORMATION PACKAGE

Menactra Side Effects May Result In Guillain Barre Syndrome Lawsuits

Menactra | Lawsuits, Lawyers | Side Effects: Guillain Barre Syndrome (GBS), Developed Weakness, Abnormal Sensations, Sensations In Arms, Sensations In Legs

The Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) are investigating five reports of Guillain Barre Syndrome (GBS) in teenagers who have taken Menactra, a new vaccine for meningitis. The vaccine's name is Meningococcal Conjugate Vaccine A, C, Y, and W135 (trade name Menactra) and is manufactured by Sanofi Pasteur.

It is not yet known whether these cases were caused by Menactra or are coincidental. The FDA and CDC have been informing the public and are investigating the situation. The FDA and CDC are asking that anyone with information of any possible cases of Guillain Barre Syndrome occurring after Menactra to report them to the Vaccine Adverse Event Reporting System (VAERS) to help the agencies further evaluate the matter.

Guillain Barre Syndrome (GBS) is a severe neurological disorder that may occur frequently in healthy individuals, either spontaneously or after certain infections. Guillain Barre Syndrome generally causes increasing weakness in the legs and arms that can require hospitalization. Meningococcal infection, which Menactra prevents, is a major cause of bacterial meningitis. Bacterial meningitis affects approximately 1 in 100,000 people annually. The infection can be life threatening: 10-14% of cases are fatal, and 11-19% of survivors can have permanent disability.

The five cases of GBS reported following administration of Menactra occurred in individuals living in New York, Ohio, Pennsylvania and New Jersey. All five patients were 17 or 18 years old and developed weakness or abnormal sensations in the arms or legs two to four weeks after vaccination. More than 2.5 million doses of Menactra vaccine have been distributed to date. The rate of GBS based on the number of cases reported following administration of Menactra is comparable to what might have been expected to occur by coincidence, even without vaccination. However, the timing of the events is also a major concern. Additionally, vaccine adverse events are not always reported to the FDA, which can potentially skew the data due to unknown cases. The government advises that adolescents and college students living in dormitories receive the vaccine.

Legal Help For Victims Affected By Menactra

If you or a loved one received the Menactra vaccine and suffered side effects, please fill out the form at the right for a free lawsuit case evaluation by a qualified drug side effects attorney or call us at 1-800-YOURLAWYER (1-800-968-7529).

Tags:  
MenactraRSS Feed

FDA and CDC Update Information on Menactra Meningococcal Vaccine and Guillain Barre Syndrome

Oct 20, 2006 | www.fda.gov
The Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) are updating a previous alert to consumers and health care providers regarding reports of Guillain Barre Syndrome (GBS) following administration of Meningococcal Conjugate Vaccine A, C, Y, and W135 (trade name Menactra), manufactured by Sanofi Pasteur. In October 2005, FDA and CDC reported 5 cases of GBS following administration of Menactra (http://www.fda.gov/bbs/topics/news/2005/new01238.html). GBS is...

Meningitis vaccine may have link to neurological disorder

Oct 10, 2005 | Dallas Morning News
Public health officials are investigating whether a new vaccine designed to help prevent meningitis, particularly among college students in dorms, could be linked to a rare neurological condition.The vaccine, called Menactra, helps protect against certain strains of meningococcal bacteria. Produced by Sanofi Pasteur, the vaccine was approved for use in January. While another vaccine was already on the market, doctors had hoped that the new formulation might offer longer immunity.Since Oct. 4,...

Menactra Vaccine May Have Tie to Brain Illness

Oct 3, 2005 | www.newsinferno.com
The Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) are alerting consumers and health care providers that five reports of Guillain Barre Syndrome (GBS) followed administration of Menactra, a new vaccine against meningitis that is manufactured by Sanofi Pasteur.  It is not known yet whether these cases were caused by the vaccine or are coincidental.  Guillain Barre Syndrome (GDS) is a serious neurological disorder that can occur, often in healthy...

FDA and CDC Issue Alert on Menactra Meningococcal Vaccine and Guillain Barre Syndrome

Sep 30, 2005 | www.fda.gov
The Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) are alerting consumers and health care providers to five reports of Guillain Barre Syndrome (GBS) following administration of Meningococcal Conjugate Vaccine A, C, Y, and W135 (trade name Menactra), manufactured by Sanofi Pasteur. It is not known yet whether these cases were caused by the vaccine or are coincidental. FDA and CDC are sharing this information with the public now and actively...

FDA Probes Vaccine's Tie to Brain Illness

Sep 30, 2005 | AP
The government is investigating five reports of teenagers who came down with a serious neurological disorder after receiving a new vaccine against meningitis. Doctors don't yet know whether the cases of Guillain Barre syndrome are related to the shot, called Menactra, or are coincidence, the Food and Drug Administration emphasized Friday. The government recommends the vaccine for adolescents and college freshmen living in dormitories, and FDA said there was no reason to change that advice but...

More Menactra News

Parker Waichman Accolades And Reviews Law Dragon Best Lawyers Find Us On Avvo Protected by Copyscape Web Copyright Protection Software php-5